We advised Laekna on the placement of new shares

Davis Polk advised Laekna, Inc. on its placement of 36,000,000 new shares for an aggregate consideration of approximately HK$587 million.

Davis Polk also advised Laekna, Inc. on its HK$791 million IPO in June 2023 and its HK$236 million placement in November 2024. The shares are listed on the Hong Kong Stock Exchange.

Founded in 2016, Laekna, Inc. is a science-driven, clinical-stage biotechnology company committed to bringing novel therapies to patients with metabolic diseases, cancer and liver fibrosis around the world. The company has initiated seven clinical trials for LAE102, LAE002 (afuresertib), LAE001 and LAE005 to address unmet medical need in obesity and cancers.

The Davis Polk team included partners Xuelin (Steve) Wang and Jason Xu, counsel Vanessa Chan and associates Michelle Chow and Yi Kai Sit. Members of the Davis Polk team are based in the Hong Kong and Beijing offices.

Copy link to share post